Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Diagnosis: Myopathy

Edward C. Smith, MD, and Dwight D. Koeberl, MD, PhD  |  Issue: July 2009  |  July 1, 2009

Phosphofructokinase deficiency (GSD type VII; PFK deficiency or Tarui disease) might be underdiagnosed because it presents with nonspecific exercise intolerance and myalgias. Until recently, Tarui disease could only be diagnosed by functional enzyme testing requiring muscle biopsy. The diagnostic evaluation has been simplified with the recent availability of gene testing. The remaining disorders are quite rare, with the exception of McArdle’s disease (GSD type V), and typically produce dynamic symptoms. Given the relatively common occurrence and characteristic clinical presentation, we will discuss McArdle’s disease in more detail here.

Prominent ragged red fibers detected by trichrome Gomori staining, fulfilling a major criterion of the modified Walker diagnostic criteria. Electron micrograph demonstrating the presence of numerous mitochondrial aggregates containing variable numbers of mitochondria (arrow). Clusters of many misshapen mitochondria were common within these aggregates (inset).
Figure 2: Histopathology, Case 3. A) Prominent ragged red fibers detected by trichrome Gomori staining, fulfilling a major criterion of the modified Walker diagnostic criteria. B) Electron micrograph demonstrating the presence of numerous mitochondrial aggregates containing variable numbers of mitochondria (arrow). Clusters of many misshapen mitochondria were common within these aggregates (inset).

Case 1

A 22-year-old male presented to the neuromuscular clinic with exertional myalgia and recurrent myoglobinuria. When the patient was a young child, his first symptoms were painful, transient contractures of his forearm finger flexors noted when climbing trees. Attacks became more frequent with age, and he first noticed dark urine associated with muscle cramping as a high school student. He did not report symptomatic improvement following short periods of rest. Physical examination was normal in clinic. There was no weakness, and no fasciculations or fixed contractures. His medical history and family history were noncontributory. Laboratory examination revealed an elevated CK (8,404 U/L; normal, 30–220 U/L), mild elevations of aspartate aminotransferase (75 U/L; normal, 15–41 U/L), and alanine aminotransferase (82 U/L; normal, 17–63 U/L). Urinalysis was negative for myoglobin. Routine muscle histology was unremarkable, but histochemical stains were not performed. EMG demonstrated mild myopathic changes. Molecular genetic testing revealed homozygosity for the common p.R49X mutation in the myophosphorylase (PYGM) gene.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The patient was diagnosed with McArdle’s disease, instructed to avoid isometric exercises, and encouraged to engage in regular aerobic exercise with a brief warm-up period. He was also instructed to consume a high-protein, low-carbohydrate diet with frequent small meals throughout the day, to ingest the equivalent of 40 grams of sucrose 30 minutes before vigorous exercise and to avoid statin medications.

McArdle’s Disease

GSD type V (McArdle’s disease or myophosphorylase deficiency) is caused by homozygous mutations in the PYGM gene, which encodes the skeletal muscle isoform of glycogen phosphorylase, also known as myophosphorylase, an essential enzyme for glycogenolysis. Because the heart and liver isoforms are not affected, the disease exclusively affects skeletal muscle.5 The typical age of onset is in late childhood. Patients develop symptoms during brief, isometric exercise such as weightlifting or during prolonged moderate intensity exercise such as jogging or swimming. Improvement in symptoms after a brief rest, the so-called “second-wind” phenomenon, is frequently reported. Approximately 50% of patients develop fixed weakness and muscle atrophy with aging.6

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 8 | Single Page
Share: 

Filed under:ConditionsSoft Tissue Pain Tagged with:DiagnosismyalgiaMyopathyPainTreatment

Related Articles
    AJPhoto / Science Source

    Tips for Diagnosing Metabolic Myopathies

    September 17, 2019

    When evaluating patients with possible myopathic symptoms, rheumatologists must consider a rare, but important, group of inherited disorders: the metabolic myopathies. However, their diagnosis often remains a challenge. Early recognition of these primary metabolic myopathies is essential to help prevent disease morbidity and mortality from rhabdomyolysis. Here, we focus on the metabolic myopathies that present…

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Fellows’ Forum Case Report: Necrotizing Autoimmune Myopathy

    December 18, 2017

    Necrotizing autoimmune myopathy (NAM) is a relatively recently discovered subgroup of inflammatory myopathies. NAM is characterized by predominant muscle fiber necrosis and regeneration with little or no inflammation.1 One subgroup of NAM is 3-hydroxy-3-methylglutaryl-CoA reductase antibody (HMGCR Ab)-related immune-mediated necrotizing myopathy (IMNM), which occurs (rarely) after statin exposure, with a rough incidence of two per…

    Myositis Mysteries

    January 1, 2008

    Why isn’t my myositis patient getting better?

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences